Comparison of cytology, HPV DNA testing and HPV 16/18 genotyping alone or combined targeting to the more balanced methodology for cervical cancer screening

Chatzistamatiou, Κimon; Moysiadis, Theodoros; Moschaki, Viktoria; Panteleris, Nikolaos; Αγοραστός, Θεόδωρος

doi:10.1016/j.ygyno.2016.04.027

Cited by 29 publications

(34 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HPV types 16 and 18 cause 60%‐70% of cervical cancers worldwide, and other HR‐HPV types cause virtually all remaining cases. Wheeler et al found that HPV16 was the most prevalent single HPV genotype in the general population and was 2‐3 times more prevalent than the other HPV genotypes . Hariri et al reported that HPV16 was also found to be the most prevalent among the genotypes classified as oncogenic in women aged ≥25 years .…”

Section: Discussionmentioning

confidence: 99%

“…According to the 2015 Interim Clinical Guidance, women positive for HPV16/18 should be referred to colposcopy immediately, but for women with other HR‐HPV genotypes, if the cytology was negative, they can be followed up within 12 months . Chatzistamatiou et al also suggested HPV testing with HPV16/18 genotyping, referring HPV16/18 positive women directly to colposcopy and HR‐HPV (non‐HPV16/18)‐positive women to reflex cytology (ASCUS threshold) as a triage method to colposcopy, which reflects the best balance between screening effectiveness and harm . However, based on our data from Chinese women, other HR‐HPV genotypes alone or mixed infections accounted for 67.17% of the total number of infections, and the prevalence of HSIL was 10.42%, although there was no significant difference in the ratio of HSIL and more severe lesions caused by non‐HPV 16/18 genotype between the age groups.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Incidence of cervical high‐grade squamous intraepithelial lesions and squamous cell carcinoma in women with high‐risk human papillomavirus and normal cervical cytology: A retrospective analysis of 1858 cases stratified by age and human papillomavirus genotype

Hong

Gao

et al. 2019

Cytopathology

View full text Add to dashboard Cite

Objective: To retrospectively analyse the incidence of high-grade squamous intraepithelial lesions (HSILs) and squamous cell carcinoma (SCC) in women of different ages with high-risk (HR) human papillomavirus (HPV) but with normal cytology test results stratified by age and HPV genotype. Methods:In total, 1858 women with HR-HPV infection but with a normal smear who received a colposcopy and biopsy between 2015 and 2016 at our institution were included. The pathological results were retrospectively analysed after stratifying by age and HPV genotype.Results: Among the 1858 cases, the HSIL% in women aged 21-29 years (10.54%) was significantly different from that in women aged 40-49 years (19.85%; P < 0.05), whereas there was no significant difference in the HSIL% among women aged 21-29 years and those in the other age groups (P > 0.05). In total, 295 cases had single HPV16 infection. The HSIL% in patients with HPV16/18 infection was >15%, and the 40-49-year age group had the highest percentage at 48.48%. For other HR-HPV infections, the HSIL and SCC incidence rate was 10.41%, and there was no significant difference among the age groups; thus, women with other types of viral infections, regardless of age, should be referred to colposcopy. Conclusions:Although HPV16 is the HPV with the highest risk, other HR-HPV infections can also cause a high percentage of HSILs and SCC in women with normal cytology. Therefore, it is necessary to refer HR-HPV-infected women aged ≥21 years for colposcopy in a timely manner to exclude potential cervical intraepithelial neoplasia and cervical cancer. K E Y W O R D Sage, cervical cancer, high-grade squamous intraepithelial lesion, human papillomavirus

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Incidence of cervical high‐grade squamous intraepithelial lesions and squamous cell carcinoma in women with high‐risk human papillomavirus and normal cervical cytology: A retrospective analysis of 1858 cases stratified by age and human papillomavirus genotype

Hong

Gao

et al. 2019

Cytopathology

View full text Add to dashboard Cite

show abstract

“…The interim clinical guidance for cervical cancer screening proposed by most of the relevant American Societies and Colleges (SGO, ASCCP, ACOG, ACS, ASCytopathol, CAP and ASCP), after the accumulating evidence on primary HPV screening and the US Food and Drug Administration (FDA) approval of the Cobas HPV test [Roche Molecular Systems, Incorporated, Pleasanton, California (http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm3947http://73.htm)] for this purpose, incorporates HPV primary screening with HPV 16/18 genotyping and reflex cytology for hrHPV (non16/18) positive women. This screening algorithm has proven more effective, and in some cases less expensive than others …”

Section: Methodsmentioning

confidence: 99%

Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women, in comparison to genotyping and cytology. Final results of the PIPAVIR study

et al. 2017

Self Cite

View full text Add to dashboard Cite

The objective of the presented cross-sectional-evaluation-screening study is the clinical evaluation of high-risk(hr)HPVE7-protein detection as a triage method to colposcopy for hrHPV-positive women, using a newly developed sandwich-ELISA-assay. Between 2013-2015, 2424 women, 30-60 years old, were recruited at the Hippokratio Hospital, Thessaloniki/Greece and the Im Mare Klinikum, Kiel/Germany, and provided a cervical sample used for Liquid Based Cytology, HPV DNA genotyping, and E7 detection using five different E7-assays: "recomWell HPV16/18/45KJhigh", "recomWell HPV16/18/45KJlow", "recomWell HPV39/51/56/59", "recomWell HPV16/31/33/35/52/58" and "recomWell HPVHRscreen" (for 16,18,31,33,35,39,45,51,52,56,58,59 E7), corresponding to different combinations of hrHPVE7-proteins. Among 1473 women with eligible samples, those positive for cytology (ASCUS+ 7.2%), and/or hrHPV DNA (19.1%) were referred for colposcopy. Cervical Intraepithelial Neoplasia grade 2 or worse (CIN2+) was detected in 27 women (1.8%). For HPV16/18-positive women with no triage, sensitivity, positive predictive value (PPV) and the number of colposcopies needed to detect one case of CIN2+ were 100.0%, 11.11% and 9.0 respectively. The respective values for E7-testing as a triage method to colposcopy ranged from 75.0-100.0%, 16.86-26.08% and 3.83-5.93. Sensitivity and PPV for cytology as triage for hrHPV(non16/18)-positive women were 45.45% and 27.77%; for E7 test the respective values ranged from 72.72-100.0% and 16.32-25.0%. Triage of HPV 16/18-positive women to colposcopy with the E7 test presents better performance than no triage, decreasing the number of colposcopies needed to detect one CIN2+. In addition, triage of hrHPV(non16/18)-positive women with E7 test presents better sensitivity and slightly worse PPV than cytology, a fact that advocates for a full molecular screening approach.

show abstract

“…In countries with an organized screening program, cervical cytology (Pap-smear) is the most common diagnostic test. Due to the low sensitivity of cytology (5)(6)(7)(8), co-testing of HPV together with cytology has been introduced in the United States (9). The World Health Organization (WHO) has recommended the use HPV test as the primary screening test and that HPV infected women are followed up with colposcopy.…”

Section: Graphical Abstractmentioning

confidence: 99%

Identification of Candidate Plasma Protein Biomarkers for Cervical Cancer Using the Multiplex Proximity Extension Assay

Berggrund

Enroth

Lundberg³

et al. 2019

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

Highlights• HPV is being introduced as the primary test in cervical cancer screening programs.• New biomarkers are needed for co-testing of women HPV positive in screening.• Analysis of plasma from women with invasive cervical cancer identified a 11-marker panel.• This signature shows high sensitivity and specificity to identify women with cancer.Human papillomavirus (HPV) is recommended as the primary test in cervical cancer screening, with co-testing by cytology for HPV-positive women to identify cervical lesions. Cytology has low sensitivity and there is a need to identify biomarkers that could identify dysplasia that are likely to progress to cancer. We searched for plasma proteins that could identify women with cervical cancer using the multiplex proximity extension assay (PEA). The abundance of 100 proteins were measured in plasma collected at the time of diagnosis of patients with invasive cervical cancer and in population controls using the Olink Multiplex panels CVD II, INF I, and ONC II. Eighty proteins showed increased levels in cases compared with controls. We identified a signature of 11 proteins (PTX3, ITGB1BP2, AXIN1, STAMPB, SRC, SIRT2, 4E-BP1, PAPPA, HB-EGF, NEMO and IL27) that distinguished cases and controls with a sensitivity of 0.96 at a specificity of 1.0. This signature was evaluated in a prospective replication cohort with samples collected before, at or after diagnosis and achieved a sensitivity of 0.78 and a specificity 0.56 separating samples collected at the time of diagnosis of invasive cancer from samples collected prior to diagnosis. No difference in abundance was seen between samples collected prior to diagnosis or after treatment as compared with population controls, indicating that this protein signature is mainly informative close to time of diagnosis. Further studies are needed to determine the optimal window in time prior to diagnosis for these biomarker candidates.

show abstract

Comparison of cytology, HPV DNA testing and HPV 16/18 genotyping alone or combined targeting to the more balanced methodology for cervical cancer screening

Cited by 29 publications

References 32 publications

Incidence of cervical high‐grade squamous intraepithelial lesions and squamous cell carcinoma in women with high‐risk human papillomavirus and normal cervical cytology: A retrospective analysis of 1858 cases stratified by age and human papillomavirus genotype

Incidence of cervical high‐grade squamous intraepithelial lesions and squamous cell carcinoma in women with high‐risk human papillomavirus and normal cervical cytology: A retrospective analysis of 1858 cases stratified by age and human papillomavirus genotype

Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women, in comparison to genotyping and cytology. Final results of the PIPAVIR study

Identification of Candidate Plasma Protein Biomarkers for Cervical Cancer Using the Multiplex Proximity Extension Assay

Contact Info

Product

Resources

About